Details of the Drug

General Information of Drug (ID: DMJIH83)

Drug Name
XmAb20717
Synonyms XmAb717
Indication
Disease Entry ICD 11 Status REF
Advanced malignancy 2A00-2F9Z Phase 1 [1]
Breast cancer 2C60-2C65 Phase 1 [2]
Melanoma 2C30 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DD1TJ8
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Not Available [3]
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Advanced malignancy
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 4.05E-03 -0.21 -1.52
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
2 ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Xencor.